Zobrazeno 1 - 10
of 47
pro vyhledávání: '"M.C. Klop"'
Autor:
Irene L.M. Reijers, Disha Rao, Judith M. Versluis, Alexander M. Menzies, Petros Dimitriadis, Michel W. Wouters, Andrew J. Spillane, Willem M.C. Klop, Annegien Broeks, Linda J.W. Bosch, Marta Lopez-Yurda, Winan J. van Houdt, Robert V. Rawson, Lindsay G. Grijpink-Ongering, Maria Gonzalez, Sten Cornelissen, Jasper Bouwman, Joyce Sanders, Elsemieke Plasmeijer, Yannick S. Elshot, Richard A. Scolyer, Bart A. van de Wiel, Daniel S. Peeper, Alexander C.J. van Akkooi, Georgina V. Long, Christian U. Blank
Publikováno v:
Reijers, I L M, Rao, D, Versluis, J M, Menzies, A M, Dimitriadis, P, Wouters, M W, Spillane, A J, Klop, W M C, Broeks, A, Bosch, L J W, Lopez-Yurda, M, van Houdt, W J, Rawson, R V, Grijpink-Ongering, L G, Gonzalez, M, Cornelissen, S, Bouwman, J, Sanders, J, Plasmeijer, E, Elshot, Y S, Scolyer, R A, van de Wiel, B A, Peeper, D S, van Akkooi, A C J, Long, G V & Blank, C U 2023, ' IFN-γ signature enables selection of neoadjuvant treatment in patients with stage III melanoma ', Journal of Experimental Medicine, vol. 220, no. 5, e20221952 . https://doi.org/10.1084/jem.20221952
Journal of experimental medicine, 220(5):e20221952. Rockefeller University Press
Journal of Experimental Medicine, 220(5):e20221952. Rockefeller University Press
Journal of experimental medicine, 220(5):e20221952. Rockefeller University Press
Journal of Experimental Medicine, 220(5):e20221952. Rockefeller University Press
Neoadjuvant ipilimumab + nivolumab has demonstrated high pathologic response rates in stage III melanoma. Patients with low intra-tumoral interferon-γ (IFN-γ) signatures are less likely to benefit. We show that domatinostat (a class I histone deace
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::17999c5aac89a5332bee79a05cb4e596
https://doi.org/10.1084/jem.20221952
https://doi.org/10.1084/jem.20221952
Autor:
Emma H.A. Stahlie, Evalyn E.A.P. Mulder, Sophie Reijers, Sara Balduzzi, Charlotte L. Zuur, Willem M.C. Klop, Bernies van der Hiel, Bart A. Van de Wiel, Michel W.J.M. Wouters, Yvonne M. Schrage, Winan J. van Houdt, Dirk J. Grunhagen, Alexander C.J. van Akkooi
Publikováno v:
Critical Reviews in Oncology/Hematology, 175. ELSEVIER SCIENCE INC
Critical Reviews in Oncology/Hematology, 175:103705. Elsevier Ireland Ltd
Critical Reviews in Oncology/Hematology, 175:103705. Elsevier Ireland Ltd
Single-agent Talimogene Laherparepvec (T-VEC) was developed for treatment of unresectable and injectable stage III-IV melanoma. Since its approval and reimbursement, studies have reported varying response rates. The purpose of this systematic review
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::afda418f16f959e55733a43646188c96
https://doi.org/10.1016/j.critrevonc.2022.103705
https://doi.org/10.1016/j.critrevonc.2022.103705
Autor:
A.C.J. van Akkooi, Judith M. Versluis, Christian U. Blank, Charlotte L. Zuur, Elisa A. Rozeman, Willem M.C. Klop, Esmée P. Hoefsmit, Lindsay G Grijpink-Ongering, María Jesús González González, Sandra Adriaansz, Robyn P. M. Saw, Sydney Ch'ng, Sten Cornelissen, J Stretch, Annegien Broeks, Ton N. Schumacher, A A Torres Acosta, Hanna Eriksson, Ron M. Kerkhoven, B.A. van de Wiel, Petros Dimitriadis, Richard A. Scolyer, Oscar Krijgsman, Daniel S. Peeper, J.B.A.G. Haanen, Omgo E. Nieweg, Karolina Sikorska, Kerwin F. Shannon, Georgina V. Long, W.J. van Houdt, A.M. Menzies, H. Mallo, Irene L.M. Reijers, Andrew J. Spillane
Publikováno v:
Nature Medicine. 27:256-263
Neoadjuvant ipilimumab plus nivolumab showed high pathologic response rates (pRRs) in patients with macroscopic stage III melanoma in the phase 1b OpACIN ( NCT02437279 ) and phase 2 OpACIN-neo ( NCT02977052 ) studies1,2. While the results are promisi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::391917477f238f400900eee0200e3f22
https://doi.org/10.1038/s41591-020-01211-7
https://doi.org/10.1038/s41591-020-01211-7
Autor:
Bart A. van de Wiel, Michel W.J.M. Wouters, Winan J. van Houdt, Alexander C.J. van Akkooi, Max F. Madu, Katarzyna Jóźwiak, Viola Franke, Willem M.C. Klop
Publikováno v:
Melanoma research, 30(2), 185-192. Lippincott Williams and Wilkins
Now effective adjuvant therapy has arrived in melanoma, accurate staging and patient selection to optimize its risk/benefit ratio is crucial. The American Joint Committee on Cancer staging system is the most widely used and validated melanoma staging
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::25add3f1123d0bc9380a77b423692ef1
http://www.scopus.com/inward/record.url?scp=85081943540&partnerID=8YFLogxK
http://www.scopus.com/inward/record.url?scp=85081943540&partnerID=8YFLogxK
Autor:
I.L.M. Reijers, A.M. Menzies, J.M. Versluis, P. Dimitriadis, M. Wouters, R.P.M. Saw, M.C. Klop, T.E. Pennington, W. Van Houdt, L.J.W. Bosch, S. Cornelissen, M.I. Lopez-Yurda, L. Grijpink-Ongering, R. Rawson, A.J. Spillane, R.A. Scolyer, B. van de Wiel, A.C.J. van Akkooi, G.V. Long, C.U. Blank
Publikováno v:
Annals of Oncology. 33:S908-S909
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f4d8545ef1cd74a5e420a41196dd97f9
https://doi.org/10.1016/j.annonc.2022.07.923
https://doi.org/10.1016/j.annonc.2022.07.923
Autor:
Ellen Passchier, Willem M.C. Klop, Wim H. van Harten, Lisette van der Molen, Arash Navran, Michiel W. M. van den Brekel, Ann Jean C.C. Beck, Martijn M. Stuiver, Valesca P. Retèl
Publikováno v:
BMC Cancer, Vol 19, Iss 1, Pp 1-10 (2019)
BMC cancer, 19(1):655. BioMed Central
Beck, A-JCC, Passchier, E, Retèl, V P, Stuiver, M M, van der Molen, L, Klop, W M C, Navran, A, van Harten, W H & van den Brekel, M W M 2019, ' Study protocol of a prospective multicenter study comparing (cost-)effectiveness of a tailored interdisciplinary head and neck rehabilitation program to usual supportive care for patients treated with concomitant chemo-or bioradiotherapy ', BMC Cancer, vol. 19, no. 1, 655 . https://doi.org/10.1186/s12885-019-5874-z
BMC Cancer, 19(1):655. BioMed Central
BMC Cancer
BMC Cancer, 19:655. BioMed Central
BMC cancer, 19(1):655. BioMed Central Ltd.
BMC cancer, 19(1):655. BioMed Central
Beck, A-JCC, Passchier, E, Retèl, V P, Stuiver, M M, van der Molen, L, Klop, W M C, Navran, A, van Harten, W H & van den Brekel, M W M 2019, ' Study protocol of a prospective multicenter study comparing (cost-)effectiveness of a tailored interdisciplinary head and neck rehabilitation program to usual supportive care for patients treated with concomitant chemo-or bioradiotherapy ', BMC Cancer, vol. 19, no. 1, 655 . https://doi.org/10.1186/s12885-019-5874-z
BMC Cancer, 19(1):655. BioMed Central
BMC Cancer
BMC Cancer, 19:655. BioMed Central
BMC cancer, 19(1):655. BioMed Central Ltd.
BACKGROUND: Since 2011, a tailored, interdisciplinary head and neck rehabilitation (IHNR) program, covered by the basic healthcare insurance, is offered to advanced head and neck cancer (HNC) patients in the Netherlands Cancer Institute (NKI). This p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::258907e6c08d8147f02505450dffc3bc
http://link.springer.com/article/10.1186/s12885-019-5874-z
http://link.springer.com/article/10.1186/s12885-019-5874-z
Parotidectomy in patients with head and neck cutaneous melanoma with cervical lymph node involvement
Autor:
Martinus M van Veen, Max F. Madu, Willem M.C. Klop, Danique M.S. Berger, Alexander C.J. van Akkooi, Alfons J. M. Balm, Wouter V. Vogel
Publikováno v:
Head & neck, 41(7), 2264-2270. John Wiley and Sons Inc.
Background Parotidectomy in melanoma of the coronal scalp and face with clinically involved cervical lymph node metastasis is based on predicted cervical lymphatic drainage described by O'Brien. Methods In total, 40 parotidectomies with en bloc thera
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::af32322011b11fe6bb61c07e7de4f529
https://doi.org/10.1002/hed.25670
https://doi.org/10.1002/hed.25670
Autor:
Willem M.C. Klop, L.E. Smeele, Rebecca T. Karsten, J.P. de Boer, Martijn M. Stuiver, Arash Navran, Frans J. M. Hilgers, L. van der Molen
Publikováno v:
Oral oncology, 88, 172-179. Elsevier Limited
Karsten, R T, Stuiver, M M, van der Molen, L, Navran, A, de Boer, J P, Hilgers, F J M, Klop, W M C & Smeele, L E 2019, ' From reactive to proactive tube feeding during chemoradiotherapy for head and neck cancer : A clinical prediction model-based approach ', Oral Oncology, vol. 88, pp. 172-179 . https://doi.org/10.1016/j.oraloncology.2018.11.031
Oral Oncology, 88, 172-179. Elsevier Limited
Karsten, R T, Stuiver, M M, van der Molen, L, Navran, A, de Boer, J P, Hilgers, F J M, Klop, W M C & Smeele, L E 2019, ' From reactive to proactive tube feeding during chemoradiotherapy for head and neck cancer : A clinical prediction model-based approach ', Oral Oncology, vol. 88, pp. 172-179 . https://doi.org/10.1016/j.oraloncology.2018.11.031
Oral Oncology, 88, 172-179. Elsevier Limited
Objectives Feeding tubes are placed unnecessarily in a proportion of head and neck cancer (HNC) patients treated with chemoradiotherapy (CRT) when prophylactic tube placement protocols are used. This may have a negative impact on the risk of long-ter
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bee0be823b01aba03044c8fe53926944
https://doi.org/10.1016/j.oraloncology.2018.11.031
https://doi.org/10.1016/j.oraloncology.2018.11.031
Autor:
J.M. Versluis, R. Elens, I.L.M. Reijers, A.M. Menzies, A.A.M. Van der Veldt, E. Kapiteijn, E.A. Rozeman, M.C. Klop, W. Van Houdt, R.P.M. Saw, C.L. Zuur, T.E. Pennington, B. van de Wiel, R.A. Scolyer, A. Broeks, A.C.J. van Akkooi, G.V. Long, C.U. Blank
Publikováno v:
Annals of Oncology. 33:S906
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d3e2de2371d8e1c152d0284ac45c01b3
https://doi.org/10.1016/j.annonc.2022.07.917
https://doi.org/10.1016/j.annonc.2022.07.917
Autor:
B.A. van de Wiel, Charlotte L. Zuur, Serigne Lo, Michel W.J.M. Wouters, Carolien Bierman, María Jesús González González, Elena Shklovskaya, Christian U. Blank, Willem M.C. Klop, Elisa A. Rozeman, Robert V. Rawson, J.B.A.G. Haanen, Omgo E. Nieweg, James S. Wilmott, Andrew J. Spillane, Robyn P. M. Saw, J.V. van Thienen, C. Adhikari, Sydney Ch'ng, A.C.J. van Akkooi, Michael T. Tetzlaff, Hanna Eriksson, Helen Rizos, Alexander Guminski, Richard A. Scolyer, Kerwin F. Shannon, W.J. van Houdt, Jonathan R. Stretch, Georgina V. Long, A.M. Menzies
Publikováno v:
Annals of Oncology, 32(6), 766-777. ELSEVIER
Background: Guidelines for pathological evaluation of neoadjuvant specimens and pathological response categories have been developed by the International Neoadjuvant Melanoma Consortium (INMC). As part of the Optimal Neo-adjuvant Combination Scheme o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ffb61a837c13200f2514a9ed7c1f22af
https://hdl.handle.net/1887/3276136
https://hdl.handle.net/1887/3276136
